ArticleScience (New York, N.Y.)2024
Impact of HLA class I functional divergence on HIV control.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 11 citations in OpenAlex.
- Towards quantifying immune diversity through HLA genomics.Nature reviews. Genetics · 2026Article
- Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy.Nature immunology · 2026Article
- HLA-II peptide-binding diversity shapes humoral immune responses and susceptibility to infections.Nature communications · 2026Article
- Article
- The HIV reservoir landscape in elite controllers.Current opinion in HIV and AIDS · 2026Review
- Recapitulating the qualities of HIV-specific CD8 + T cells from spontaneous controllers.Current opinion in HIV and AIDS · 2026Review
- The viral and host genomic landscape of human T-cell leukemia virus type I in Peru.Virology journal · 2026Article
- Full-length next-generation sequencing of 11 HLA loci of more than 1000 individuals from clinical cohorts in East and West Africa.bioRxiv : the preprint server for biology · 2025Article
- Sex-Dependent Influence of Major Histocompatibility Complex Diversity on Fitness in a Social Mammal.Molecular ecology · 2025Article
- Donor HLA-DQ genetic and functional divergence affect the control of BK polyoma virus infection after kidney transplantation.Science advances · 2025Article
- Persistent elite controllers as the key model to identify permanent HIV remission.Current opinion in HIV and AIDS · 2025Review
- Article
- HLA-C Peptide Repertoires as Predictors of Clinical Response during Early SARS-CoV-2 Infection.Life (Basel, Switzerland) · 2024Article
- Modelling HIV-1 control and remission.NPJ systems biology and applications · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 1 country.
Mathias Viard *Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute Bethesda, MD, USA.ORCID 0000-0002-1737-8021
Colm O'hUigin *Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute Bethesda, MD, USA.ORCID 0000-0001-5404-5173
Yuko YukiBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute Bethesda, MD, USA.ORCID 0000-0003-1721-6003
Arman A BashirovaBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute Bethesda, MD, USA.ORCID 0000-0001-9188-0178
David R CollinsRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.ORCID 0000-0001-7903-346X
Jonathan M UrbachRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.ORCID 0000-0003-0597-2848
Steven WolinskyDivision of Infectious Diseases, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-9625-6697
Susan BuchbinderBridge HIV, San Francisco Department of Public Health, San Francisco, CA, USA.ORCID 0000-0003-2404-0712
Gregory D KirkDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
James J GoedertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-6134-1472
Nelson L MichaelUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID 0000-0001-5882-5548
David W HaasDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0000-0002-5813-1594
Steven G DeeksDepartment of Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0001-6371-747X
Bruce D WalkerRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.ORCID 0000-0001-6122-9245
Xu YuRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.ORCID 0000-0002-8295-884X
Mary CarringtonBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute Bethesda, MD, USA.ORCID 0000-0002-2692-2180
Frederick National Laboratory for Cancer Research · USRagon Institute of MGH, MIT and Harvard · USUniversity of California, San Francisco · USHoward Hughes Medical Institute · USJohns Hopkins University · USNational Institutes of Health · USNorthwestern University · USVanderbilt University · USWalter Reed Army Institute of Research · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MLeadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MWOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5MUCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MThe impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4MVirology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6MEngaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MZONA-FREE HAMSTER OVA ASSAY AS AN INDICATOR OF MALE FERTILITYM01RR000425 · NCRR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI ANDERSON, GAIL V · 1985 to 2011
$74.2MBLRD VA I01 BX000207NCATS NIH HHS KL2 TR001432NCATS NIH HHS TL1 TR001431NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000058NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR000170NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR001111NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NCI NIH HHS 75N91019D00024NCRR NIH HHS M01 RR000046NCRR NIH HHS M01 RR000425NCRR NIH HHS UL1 RR024156NCRR NIH HHS UL1 RR024160NCRR NIH HHS UL1 RR024996NCRR NIH HHS UL1 RR025008NCRR NIH HHS UL1 RR025747NCRR NIH HHS UL1 RR025777NCRR NIH HHS UL1 RR025780NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI073961NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI058740NIAID NIH HHS R01 AI077505NIAID NIH HHS U01 AI025859NIAID NIH HHS U01 AI025868NIAID NIH HHS U01 AI027658NIAID NIH HHS U01 AI027666NIAID NIH HHS U01 AI027675NIAID NIH HHS U01 AI032782NIAID NIH HHS U01 AI034853NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI046370NIAID NIH HHS U01 AI046376NIAID NIH HHS U01 AI069412NIAID NIH HHS U01 AI069415NIAID NIH HHS U01 AI069418NIAID NIH HHS U01 AI069419NIAID NIH HHS U01 AI069423NIAID NIH HHS U01 AI069424NIAID NIH HHS U01 AI069428NIAID NIH HHS U01 AI069432NIAID NIH HHS U01 AI069434NIAID NIH HHS U01 AI069439NIAID NIH HHS U01 AI069447NIAID NIH HHS U01 AI069450NIAID NIH HHS U01 AI069452NIAID NIH HHS U01 AI069465NIAID NIH HHS U01 AI069467NIAID NIH HHS U01 AI069470NIAID NIH HHS U01 AI069471NIAID NIH HHS U01 AI069472NIAID NIH HHS U01 AI069474NIAID NIH HHS U01 AI069477NIAID NIH HHS U01 AI069481NIAID NIH HHS U01 AI069484NIAID NIH HHS U01 AI069494NIAID NIH HHS U01 AI069495NIAID NIH HHS U01 AI069496NIAID NIH HHS U01 AI069501NIAID NIH HHS U01 AI069502NIAID NIH HHS U01 AI069503NIAID NIH HHS U01 AI069511NIAID NIH HHS U01 AI069513NIAID NIH HHS U01 AI069532NIAID NIH HHS U01 AI069534NIAID NIH HHS U01 AI069556NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069439NIAID NIH HHS UM1 AI069481NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI069503NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI106701NIA NIH HHS U54 AG062334NIMH NIH HHS P30 MH116867NIMH NIH HHS P30 MH133399
Abstract
Heterozygosity of
Indexed as
HeterozygoteHIV InfectionsHLA-B AntigensAdultAgedAllelesDisease ProgressionFemaleHumansMaleMiddle AgedPeptidesYoung AdultHLA-B AntigensPeptides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.